LRI Investments LLC Decreases Holdings in Johnson & Johnson $JNJ

LRI Investments LLC decreased its position in shares of Johnson & Johnson (NYSE:JNJ) by 1.0% during the 2nd quarter, Holdings Channel.com reports. The fund owned 14,120 shares of the company’s stock after selling 140 shares during the period. LRI Investments LLC’s holdings in Johnson & Johnson were worth $2,157,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. GFG Capital LLC purchased a new stake in Johnson & Johnson in the 2nd quarter valued at approximately $35,000. Highline Wealth Partners LLC increased its holdings in shares of Johnson & Johnson by 51.8% during the 1st quarter. Highline Wealth Partners LLC now owns 252 shares of the company’s stock worth $42,000 after buying an additional 86 shares during the last quarter. Stone House Investment Management LLC acquired a new stake in shares of Johnson & Johnson during the 1st quarter worth $47,000. 1248 Management LLC acquired a new stake in shares of Johnson & Johnson during the 1st quarter worth $48,000. Finally, von Borstel & Associates Inc. acquired a new stake in shares of Johnson & Johnson during the 1st quarter worth $49,000. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Stock Down 0.0%

Shares of Johnson & Johnson stock opened at $190.88 on Wednesday. The business has a 50-day moving average of $179.28 and a 200-day moving average of $164.16. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.01 and a quick ratio of 0.76. The company has a market capitalization of $459.70 billion, a PE ratio of 20.41, a P/E/G ratio of 2.40 and a beta of 0.40. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $194.40.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Wednesday, August 30th. The company reported $2.26 earnings per share for the quarter. The company had revenue of $24.02 billion during the quarter. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%. As a group, equities analysts forecast that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 9th. Stockholders of record on Tuesday, November 25th will be given a dividend of $1.30 per share. The ex-dividend date of this dividend is Tuesday, November 25th. This represents a $5.20 annualized dividend and a dividend yield of 2.7%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 55.61%.

Insider Activity at Johnson & Johnson

In other news, EVP Jennifer L. Taubert sold 56,471 shares of the stock in a transaction dated Thursday, September 4th. The shares were sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the transaction, the executive vice president owned 178,013 shares of the company’s stock, valued at approximately $31,652,491.53. This trade represents a 24.08% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 0.16% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on JNJ. Guggenheim upgraded Johnson & Johnson from a “neutral” rating to a “buy” rating and increased their price target for the company from $167.00 to $206.00 in a report on Tuesday, September 23rd. Erste Group Bank upgraded Johnson & Johnson from a “hold” rating to a “buy” rating in a report on Wednesday, July 23rd. Citigroup increased their price target on Johnson & Johnson from $200.00 to $213.00 and gave the company a “buy” rating in a report on Tuesday, October 7th. Cowen reiterated a “buy” rating on shares of Johnson & Johnson in a report on Tuesday. Finally, Morgan Stanley increased their price target on Johnson & Johnson from $176.00 to $178.00 and gave the company an “equal weight” rating in a report on Friday, October 10th. Two analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and eight have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $193.88.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.